Kalamazoo County sets $200 monthly copay for GLP-1 anti-obesity drugs in stopgap change

Kalamazoo County commissioners voted Aug. 5 to change employee health-plan coverage for GLP-1 anti-obesity medications by adopting a temporary $200 monthly co-pay for prescriptions labeled and billed as treating obesity. The change excludes prescriptions for diabetes and is intended as a one-year stopgap while the county explores longer-term, legally compliant alternatives and market developments.

HR Director Sharon Brown told commissioners the drugs are driving volatility in plan costs and that the county's base illustrative full-year exposure was about $1.6 million. "These medications are relatively new," she said, and insurers and manufacturers are experimenting with coverage and direct-to-consumer discounts. Brown presented three options: increase patient cost-sharing (including a 50/50 split or a fixed-dollar copay), pursue a legally complex reimbursement-for-direct-purchase approach, or remove coverage and redirect resources to wellness programs. The board debated clinical benefits, fairness across employee income levels, and employer fiscal responsibility.

Vice Chair (speaker 16) framed the board's decision as a temporary, fiscally necessary compromise: the $200 copay was chosen as an interim measure to meaningfully reduce the county's plan exposure without completely eliminating access. Commissioners required quarterly data reporting on utilization and cost impacts and directed HR to return with a six-month presentation about outcomes and alternative models, including potential guardrails that would limit coverage to prescribers and clinical eligibility criteria.